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EDITORIAL
Many of the highly effective agents in contemporary oncology, including the anthracyclines and 
trastuzumab, are known to increase the risk of cardiac events in both the short and long term. As these 
agents are often used to obtain a cure, the means of maximising their benefits while reducing 
the risk to the heart has become a priority when managing the patient with a malignancy. In addition, 
the novel biologic therapies, designed to fulfil unmet needs in oncology, require the development of 
strategies for risk detection and management that aim to reduce the risk of cardiac toxicity.
Firstly, cardiac toxicity may be reduced by limiting the patient’s exposure to radiotherapy and/or 
chemotherapy to the required minimum to effect cure. Furthermore, understanding the molecular 
mechanisms by which chemotherapeutic agents adversely affect the heart gives insight into the 
potential for discovering methods that limit the damage they may cause. 
Once the patient has been exposed to a potentially harmful agent, it is most important to have at 
one’s disposal the tools for the early detection of cardiac injury, to understand the implications of 
any abnormal finding and to be able to act timeously to diminish the damage.
Clearly, being at risk from cardiotoxic agents does not diminish the risk of developing cardiac disease 
from other causes. Thus, a vigilant search for risk factors such as hypertension, hypercholesterolaemia 
and diabetes should form part of the diagnostic work-up and monitoring plan and any abnormality 
should be treated aggressively. 
Although there has been substantial progress in the treatment of cancer, it has resulted in a greater 
possibility of cardiac problems emerging which may in turn increase morbidity and mortality. If for no 
other reason, this makes co-operation between the cardiologist and oncologist essential. Recently, 
cardio-oncology has been established as a specific subspecialty in the USA and in Europe. Because this 
development is much less likely in South Africa, it behoves all cardiologists to inform themselves on 
the management of this group of patients. 
This issue of SA Heart provides an update on the effects of cancer therapy on the heart. The various 
treatment modalities and classes of chemotherapeutic agents are discussed. The early detection, 
prevention and therapy of cardiotoxicity is highlighted. Hopefully this publication will stimulate interest 
in the fascinating field of cardio-oncology – bringing together the molecular and clinical aspects of 
cardiotoxicity – and result in a change in attitude to patients with cancer to their eventual benefit. 
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